PriceTargets.com logo

Chromocell Therapeutics - CHRO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.65 As of 12/3/2024 01:02 PM ET
▼ -0.0145 (-2.18%)

This chart shows the closing price for CHRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Chromocell Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHRO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Chromocell Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.65.

This chart shows the closing price for CHRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Chromocell Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/18/2024Alliance Global PartnersInitiated CoverageBuy
(Data available from 12/3/2019 forward)

News Sentiment Rating

-0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.

Chromocell Therapeutics

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Read More

Today's Range

Now: $0.65
Low: $0.63
High: $0.69

50 Day Range

MA: $0.67
Low: $0.55
High: $1.01

52 Week Range

Now: $0.65
Low: $0.45
High: $6.00

Volume

6,656 shs

Average Volume

59,856 shs

Market Capitalization

$3.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Chromocell Therapeutics?

The following Wall Street analysts have issued reports on Chromocell Therapeutics in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for CHRO.

What is the current price target for Chromocell Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Chromocell Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Chromocell Therapeutics in the next year.
View the latest price targets for CHRO.

What is the current consensus analyst rating for Chromocell Therapeutics?

Chromocell Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CHRO will outperform the market and that investors should add to their positions of Chromocell Therapeutics.
View the latest ratings for CHRO.

What other companies compete with Chromocell Therapeutics?

Other companies that are similar to Chromocell Therapeutics include Akari Therapeutics, Bright Green, Minerva Neurosciences, NKGen Biotech and Sol-Gel Technologies. Learn More about companies similar to Chromocell Therapeutics.

How do I contact Chromocell Therapeutics' investor relations team?

Chromocell Therapeutics' physical mailing address is 4400 Route 9 South, Suite 1000, Freehold, NJ 07728, United States. The company's listed phone number is 732-514-2636 and its investor relations email address is [email protected]. The official website for Chromocell Therapeutics is chromocell.com. Learn More about contacing Chromocell Therapeutics investor relations.